Study of genetic alterations, inherited or acquired, that increase the risk or drive cancers and many other diseases had remained mostly confined to coding sequences of the human genome. Data from genome wide associations studies, development of the Encyclopedia of DNA Elements (ENCODE), and a spurt in detection of driver somatic mutations have shifted focus towards noncoding regions of the human genome. The majority of genetic variants robustly associated with cancers and other syndromes identified through genome wide studies are located within noncoding regulatory regions of the genome. Genome wide techniques have put an emphasis on the role of three-dimensional chromosomal structures and cis-acting elements in regulations of different genes. The variants within noncoding genomic regions can potentially alter a number of regulatory elements including promoters, enhancers, insulators, noncoding long RNAs and others that affect cancers and various diseases through altered expression of critical genes. With effect of genetic alterations within regulatory elements dependent on other partner molecules like transcription factors and histone marks, an understanding of such modifications can potentially identify extended therapeutic targets. That concept has been augmented by the detection of driver somatic noncoding mutations within the promoter region of the telomerase reverse transcriptase (TERT) gene in different cancers. The acquired somatic noncoding mutations within different regulatory elements are now being reported in different cancers with an increased regularity. In this review we discuss the occurrence and impact of germline and somatic alterations within the TERT promoter and other genomic regulatory elements.
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Completion of human genome sequencing followed by a decade long technological advancements resulted in facile generation of genome wide data from cancers and other diseases. Sequencing initiatives like The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) have led to the generation of extensive catalogues of genetic alterations across the different cancer types. 1, 2 Exhaustive genetic studies have culminated in identification of the genes that are recurrently mutated in main human cancer types. [3] [4] [5] [6] From the emphasis on genetic alterations within the protein coding sequences, the genome wide association studies and simultaneous development of the Encyclopedia of DNA Elements (ENCODE) project has brought to forth the importance of genomic regulatory elements within the human genome. 7, 8 Genome wide techniques have underscored the role of spatial organization of the genome and cisacting elements in gene regulation. [9] [10] [11] The influence of regulatory elements on cancer development has been known for a long time. Rearrangements and translocations leading to juxtaposition of cancer associated genes with enhancers and promoters result in increased expression of oncogenes in different malignancies. 12 Chromosomal inversions and translocations frequently lead to formation of fusion oncogenes via rearrangement of coding sequences of the involved partner genes. 13 The BCR-ABL chromosome, also known as the Philadelphia chromosome, results from translocations involving 9q34 and 22q11 causing head to tail fusion of breakpoint cluster region (BCR) gene on chromosome 22 with the cellular homologue of the Abelson (c-ABL) viral oncogene on chromosome 9. 14 The rearrangement, frequent in adult acute lymphoblastic leukemia, places the latter oncogene under control of ubiquitously expressed BCR promoter. 15 The most common types of somatic genetic alterations nevertheless until recently were considered as exclusive preserve of the coding sequences that cause changes in protein functions. Through the discovery of activating mutations in RAS genes to identification of actionable mutations in a repertoire of oncogenes and tumor suppressor genes, seven decades after Theodor Boveri proposed that cancer was caused by chromosomal derangement leading to uncontrolled cell division, has ushered a revolution in cancer medicine. 16, 17 Some of the prime examples where mutations have been targeted for treatment of advanced diseases with success include melanoma in which treatment of metastasized disease with vemurafenib and dabrafenib specifically target the V600E mutation in BRAF or its downstream effectors. 18, 19 The identification of noncoding mutations within the socalled dark matter of the human genome that influence carcinogenesis through alteration of genomic regulatory elements has begun to gain increased credence. 6 The mutations in noncoding regions can potentially impact gene expressions through alterations of regulatory elements like promoters, enhancers, insulators, long noncoding RNAs and other regulatory elements through interaction with partner elements (Fig. 1) . [20] [21] [22] [23] In this review, we have focused on occurrence and impact of genetic alterations within the TERT promoter and other regulatory elements through, hitherto, accrued knowledge.
Germline Alterations Within Genomic Regulatory Elements
Genome wide association studies have identified over 150 mostly low-penetrant susceptibility loci for different cancers with a vast majority of robustly disease-associated polymorphisms located within noncoding regions of the genome. [24] [25] [26] It is assumed that at some loci multiple and independent rather than single risk associated polymorphisms may be functionally involved in the disease predisposition. 24 Studies have shown almost 60% of polymorphisms identified within noncoding regions to be located within DNase I hypersensitive (DHS) sites. 27 Such sites reflect occupancy of DNA binding proteins like transcription factors. The polymorphisms within the sequences identified in various genome wide studies exert influence by altering binding to transcription factor sites leading to variable gene expression through complex molecular traits. 28, 29 The polymorphisms associated with traits relevant to particular cell type, in chromatin and transcriptome profiling, have also been shown to be enriched in extended enhancers. 30 Several loci that emerged as prominently associated with various cancers and diseases included a gene desert region on chromosome 8q24. 31 The polymorphisms within the distinct linkage disequilibrium blocks in that 1.2 Mb gene desert region on 8q24 are associated with risk of chronic lymphocytic leukemia, prostate, colorectal, ovarian, breast and bladder cancers. [31] [32] [33] [34] The region contains several transcriptional enhancers and is part of a single chromatin interaction topologic domain that includes the MYC gene. 11, 20, 33, 35 The plausibility of MYC regulation through enhancers within the gene desert enriched in cancers associated polymorphisms has been experimentally demonstrated in different studies. 36, 37 For example, a polymorphism represented by rs698367 at chromosome 8q24 that increases the risk of colorectal cancer by 1.5-fold was shown to be contained within an enhancer element at a site occupied by the Wnt regulated transcription factor TCF4 that influences MYC expression. 36 The rs6983267 polymorphism affects the binding of TCF4 in the regulatory element, which is functional in colorectal cancer cells. 36 Another study showed that the alleles of the rs6983267 polymorphism differentially bind transcription factor 7-like 2 (TCF7L2) and the region containing polymorphism physically interacts with MYC. 37 Knockout mice with the deleted enhancer containing the rs6983267 polymorphism, which is 335 kb upstream of MYC, were markedly resistant to Wnt signaling dependent intestinal tumorigenesis induced by the APCmin mutation. 38 Another colorectal cancer associated polymorphism represented by rs16888589 at 8q23.3 is located in the region that, as shown by chromosome capture conformation, interacts with the promoter of the gene for eukaryotic translation initiation factor 3, subunit H (EIF3H). Increased expression of EIF3H leads to increased tumor growth and invasiveness in colorectal cancer. 39 One of the prostate cancer associated polymorphisms on 8q24 represented by rs11986220 is located within an enhancer region with risk associated allele facilitating increased FoxA1 binding and increased androgen responsiveness in prostate cancer cell lines. 35 The prostate cancer risk-associated allele of the rs7463708 polymorphism at 8q24 results in increased expression of long noncoding RNA, PCAT1 through modulating ONECUT2 and androgen receptor binding at a distal enhancer. 40 LMO1 was identified as a neuroblastoma oncogene through integrative genomics including a genome wide association study. 41 Fine mapping and imputation across the locus identified a highly associated rs2168101 polymorphism within a super-enhancer element in the first intron of LMO1 that influences neuroblastoma susceptibility through differential GATA transcription factor binding and modulation of LMO1 expression leading to an oncogenic dependency in tumor cells. 42 An example of copy number variation within a regulatory region is illustrated by an intergenic breast cancer risk locus approximately 400 kb upstream of IGFBF5 on chromosome 2q35, which overlaps an intergenic ERa-bound enhancer that loops to the IGFBP5 promoter. The enhancer copy number variation correlated with modified ERa binding and monoallelic repression of IGFBF5, following the estrogen treatment and was shown to be associated inversely with breast cancer risk in a dosedependent manner. 43 A functional noncoding variation in a disease other than cancer is illustrated by the association of the rs35705950 polymorphism, identified through linkage analysis, with familial interstitial pneumonia and idiopathic pulmonary fibrosis. The minor allele of rs35705950 located 3 kb upstream of the transcription start site, upregulates the MUC5B expression. 44, 45 Similarly, the variant allele of the rs2435357 polymorphism that disrupts SOX10 binding within an enhancer element in intron 1 of the RET gene was demonstrated to cause a four-fold increase in the risk of Hirschsprung disease. 46 Two other risk associated polymorphisms within cis regulatory elements that bind Gata2 and Rarb, rs2506030 and rs7069590, 125 and 18 kb upstream, respectively, also affect RET transcription. 47 The study on cell lines demonstrated that reduced RET expression exerts effect on both its positive and negative feedback components. The presence of combination of cis regulatory variants synergistically reduces RET expression and affects its gene regulatory network. 47 Most of the germline mutations in genes that impart high or moderate risk of cancers alter coding sequences with diverse functional effects on tumor suppressors and oncogenes like RB1, CDKN2A, APC, TP53, RET, CDK4 and others. 25, [48] [49] [50] [51] [52] Germline noncoding mutations within cancer predisposing genes are, hitherto, distinctively rare. 25 Nevertheless, some of those genes besides germline coding mutations are also known to inherit alterations within the noncoding sequences with functional ramifications. 53 Functional germline noncoding mutations within the 5 0 -untranslated region (UTR) and in an intron of CDKN2A occur in familial-melanoma. [53] [54] [55] Germline mutations in the 5 0 UTR of CDKN2A were experimentally shown to result in reduced promoter activity. 53 A germline mutation IVS2-105 A/G deep in intron 2 of CDKN2A detected in six English melanoma families results in an aberrant splicing. 55 While, most of the germline WT1 mutations predispose carriers to Wilms tumor, genitourinary abnormalities and renal dysfunction; the intronic mutations that alter the relative abundance of WT1 isoform cause Frasier syndrome. 25, 56 Genetic disorders other than cancers affected by noncoding germline mutations include autosomal-dominant corneal endothelial dystrophy 1 (CHED) 1 and posterior polymorphous corneal dystrophy 1 (PPCD1) that were mapped to the overlapping loci on the short arm of chromosome 20. Targeted and whole genome sequencing approach identified pathogenic variants in the conserved region of OVOL2 proximal promoter in the index families, c.-339_361 dup for CHED1 and c.370 T > C for PPCD1 that increased transcriptional activity. 57 A major impetus for the role of noncoding mutations in cancers came through the discovery of functional alterations within the core promoter of the gene encoding the catalytic subunit of telomerase reverse transcriptase (TERT). [58] [59] [60] The initial identification of the TERT promoter mutations came through a study of a multigenerational melanoma pedigree. 58 Multipoint linkage analysis followed by deep sequencing of the 2.2 Mb linked region on chromosome 5p resulted in detection of a A > C (T > G) mutation that segregated with the disease. The germline mutation was placed at 257 bp from ATG start site of the TERT gene in close proximity to the transcription start and it created a CCGGAA/T consensus binding site for E-twenty six/ternary complex (ETS/TCF) transcription factors. The mutation carriers in the family were characterized by an early onset of melanoma and rapid progression leading to an early death. Two individuals with the germline mutation, who survived beyond the median age, also presented a host of other malignancies. 58 Prior to the identification of activating mutations within the promoter, a number of low-penetrant common polymorphisms at and around the TERT locus had been associated with multiple cancers. 61 Pertinently, the loss of function monoallelic and biallelic missense germline mutations in the TERT gene are causal in dyskeratosis congenita, a multisystem syndrome characterized by bone marrow failure, mucocutaneous abnormalities and predisposition to some cancers. 62 Figure 1. Regulatory elements. Regulation of genetic transcription involves proximal promoter as well as distal regulatory elements. The core promoter with binding sites for transcription factors and RNA polymerase can be further regulated by multiple distal enhancers, interspersed with silencers and insulator elements. The variation within those regulatory elements can lead to transcriptional deregulation. [21] [22] [23] Special Section Paper
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Acquired Somatic Alterations Affecting Regulatory Elements
The theoretical considerations about the required number of driver mutations in solid tumors compared to the actual number of mutations observed until the advent of whole genome sequencing initiatives had left a void because of technical issues. 63 Moreover, an overt focus on the coding sequence, in part due to lack of understanding until the ENCODE data and technical innovations, the functional relevance of vast noncoding genome for potential driver mutations had remained undetermined. Conventional convergence between germline and somatic genetics prompted a screening of the TERT promoter in melanoma cell lines derived from metastasized tumors from unrelated patients following the discovery of the highly penetrant germline mutation in the melanoma family. 58 That screening led to the discovery of highly recurrent mutations at 2124 and 2146 bp positions from the ATG site of the gene. The C > T (G > A) mutations at both 2124 and 2146 bp positions, like the 257 A > C germline mutation in the melanoma family, create the consensus binding sites for ETS/ TCF transcription factors. Besides the 2124 C > T and 2146 C > T mutations, other alterations detected in the TERT promoter included CC > TT tandem base pair changes at 2124/-125 and 2138/-139 bp positions, which also lead to creation of the CCGGAA/T consensus sites. Overall the frequency of the TERT promoter mutations in the series of melanoma cell lines derived from metastasized tumors exceeded that of mutations in the BRAF gene. 58 Following the initial discovery, various other studies showed that the TERT promoter mutations were frequent in many cancer types that included glioma, bladder cancer, hepatocellular carcinomas, thyroid cancers, non-melanoma skin cancers and others. [64] [65] [66] [67] [68] The discovery of TERT promoter mutations at a high frequency in different cancers instigated several initiatives aimed at genome wide discovery of alterations within noncoding regions ( Table 1) . The first study, carried out on 863 human tumors from TCGA and other sources to scan the genome for noncoding mutations with potential regulatory impact, resulted in the identification of recurrent mutations in regulatory elements upstream of the PLEKHS1, WDR74 and SDHD genes, besides those in the TERT promoter. 69 Another study carried out on 505 tumor genomes across 14 different cancer types to systematically screen association between mutations in regulatory elements and changes in RNA-levels, identified alterations in promoter regions of PLEKHS1 and DPH3.
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The mutations located in a bidirectional promoter shared between DPH3 and OXNAD1 were present in about 10% of melanoma and 40% of skin basal cell and squamous cell carcinoma. 71 Mutations in the DPH3 promoter overlapped the predicted ETS sites and chromatin immunoprecipitation sequences peaks for transcription factors like ELK1-ELF1-ELK4. High frequency of the TERT and DPH3 promoter mutations were also reported in a study based on identification of clustered somatic mutations in skin malignancies, which also revealed other recurrent hotspot mutations within ETS and Sp1 binding motifs in proximal promoters. 72 Significantly large number of mutations in the WDR74 promoter were also reported in liver cancer, besides in the promoters of TERT, MED16 and TFP12 and in the 3'UTR of BCL6 and AFF4. 73 Promoter mutations in PLEKHS1, TBC1D12, WDR74 and enrichment of mutations in two long noncoding RNA, MALAT1 and NEAT1 were reported in breast cancer. 74 In another report, a significant enrichment of somatic mutations within a set of regulatory elements controlling estrogen receptor-a (ESR1) was observed in 7% of the receptor positive breast cancers. 75 Similarly frequent A > T point mutations were found at CTCF7 cohesin binding sites (CBS) in microsatellite stable colorectal tumors. 76 One of the earliest reports of noncoding mutations affecting an enhancer element pertains to the acquired somatic insertions upstream of TAL1 oncogene in T-cell acute lymphoblastic leukemia (T-ALL). 77 Similarly, a C > T somatic noncoding mutation 4 kb upstream of the transcriptional site of the LMO1 oncogene was also reported in T-ALL. 78 Other noncoding mutations reported include those in the NFKBIE promoter in desmoplastic melanoma and at the transcription start site of RPS27 in melanoma. 79, 80 Mutations within the 3' untranslated regions of NOTCH1 and CD274 have been reported in chronic lymphocytic leukemia and multiple cancers, respectively. 81, 82 Another instance of recurrent noncoding tumor specific mutations included a small intergenic region of chromosome 9p13 in chronic lymphocytic leukemia. 81 Some of the somatic genetic rearrangements result in juxtaposition of enhancer elements of immunoglobulin genes IGH, IGK and IGL with MYC on chromosome 8q24 leading to oncogenic MYC overexpression in Burkitt lymphoma and diffuse large B-cell lymphoma. 83, 84 In medulloblastoma, somatic structural variants result in placement of growth factor independent 1 family proto-oncogenes, GFI1 or GFI2B, proximal to active enhancers and super-enhancers. 85 Rearrangements of a single oncogenic enhancer on chromosome 3q ectopically activate EVI1 and confer GATA2 functional haploinsufficiency in acute myeloid leukemia. 86 Recurrent fusion of the 5' untranslated region of TMPRSS2 to EGR and ETV1 has been shown to mediate overexpression of the ETS family transcription factors in prostate cancer. 87 
Distribution and Impact of Noncoding Mutations
By far the most frequent regulatory noncoding mutations that influence carcinogenesis through increased expression are the alterations within the core promoter of the TERT gene. 66 TERT constitutes the rate-limiting catalytic subunit of telomerase enzyme that elongates telomeres at chromosomal ends. 88 With the exception of germ and stem cells, TERT expression remains repressed in most human somatic cells. 89 The absence of telomerase in somatic cells leads to gradual attrition of telomere repeats due to intrinsic limitation of DNA replication process called 'end-replication problem'. 90 In contrast, in over 90% of human malignancies rejuvenated telomerase affords an unlimited replicative potential, which constitutes one of the hallmarks of cancers. 91 The exact mechanism of re-expression of TERT had been vaguely attributed to epigenetic changes within the promoter of the gene that harbors binding sites for numerous transcription factors. 92 The discovery of TERT promoter mutations, initially as a germline high-penetrant mutation followed by highly recurrent and frequent somatic mutations within the promoter that increase TERT expression through creation of consensus binding sites for ETS/TCF transcription factors, provided a definite mechanism for cancer specific telomerase regeneration, particularly in cancers arising from tissues with low rates of self-renewal. 58, 60, 64 Besides melanoma, TERT promoter mutations are frequent in many cancers and an initial study on 60 different cancer types showed tumors based on frequencies can be divided into high and low categories, with more or <15%, respectively. 64 Depending on prevalence, it was hypothesized that the TERT promoter mutations occur mainly in tumors that derive from tissues with low rates of self-renewal. 64, 89 Different studies have shown that mutations in TERT not only vary between cancer types but also depend on histological subtypes. 66 The promoter mutations in general represent characteristic alterations of mainly adult cancers and are rare in pediatric cancers and tumors from young adults. 60 The available data indicate that the TERT promoter mutations tend to be distributed mainly in specific subtypes and in many cancers associate with adverse disease outcomes. 66 While in primary melanoma the reported frequency of TERT promoter mutations approximates about 40%, the frequency in metastasized melanoma exceeds 70 and 80% in desmoplastic melanoma; in acral and mucosal melanoma, those mutations are rare (Table 2) . 59, 79, [93] [94] [95] The promoter mutations while absent in melanocytic nevi have been shown to occur in intermediate succinate dehydrogenase complex subunit D; PLEKHS1: pleckstrin homology domain containing S1; TFPI2: tissue factor pathway inhibitor 2; MED16: mediator complex subunit 16; TBC1D12: TBC1 domain family member 12; NDUFB9: NADH:ubiquinone oxidoreductase subunit B9; PAX5: paired box 5; TAL1: TAL bHLH transcription factor 1: erythroid differentiation factor; RPS27: ribosomal protein S27; ESR1: estrogen receptor 1; MRPS31: mitochondrial ribosomal protein S31; CD274: CD274 molecule; MALAT1: metastasis associated lung adenocarcinoma transcript 1; NEAT1: nuclear paraspeckle assembly transcript 1.
dysplastic lesions. 96 In melanoma the TERT promoter mutations tend to co-occur with BRAF/NRAS and CDKN2A alterations. 93 The promoter mutations have been shown to provide a direct link between MAPK pathway activation and TERT expression. 97 RAS-ERK signaling in melanomas with mutant BRAF has been shown to be critical for regulating active chromatin state and recruitment of RNA polymerase II at mutant TERT promoter. 98 Various studies showed that TERT promoter mutations were not only the most frequent somatic alterations in melanoma but also associated with advanced disease stages and markers of poor outcome including increased Breslow thickness, tumor ulceration and growth rate. 93 Some follow-up studies also showed association of TERT promoter mutations with disease and melanoma specific survival, particularly in combination with BRAF/NRAS mutations. 93, 95, 99 Keratinocyte skin cancers, both basal and squamous cell, have been shown to harbor the TERT promoter mutation at a high frequency.
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The TERT promoter mutations are shown to be particularly frequent in different adult gliomas, with highest frequency reported in primary glioblastoma followed by oligodendroglioma, oligoastrocytoma and astrocytoma. 64, [101] [102] [103] [104] The distribution and pattern of TERT promoter mutations together with mutations in IDH1/IDH2 and deletions at chromosomes 1p/19q in gliomas follow histological subgroup classification with distinct survival patterns. [105] [106] [107] Additional cancers with frequent TERT promoter mutations include bladder cancer, thyroid cancers, heptatocellular carcinoma, and others. 65, [108] [109] [110] [111] The TERT promoter mutations have been described as a switch between adenomas and carcinomas of liver; those also associate with poor disease free and overall survival. [112] [113] [114] In bladder cancer, the TERT promoter mutations have been shown to be the most frequent somatic alterations in both invasive and non-invasive tumors and tend to co-occur with FGFR3 mutations that are more frequent in non-invasive than invasive tumors. 105 Further the promoter mutations associate with patient survival and disease recurrence. 65, 105 Regulatory Mutations: Mechanism of Effect
The genetic variations within the regulatory elements by definition can exert influence through transcriptional regulation. The regulatory effects of the promoter mutations that drive cancer through increased TERT transcription have been extensively investigated. Consistent with initial data from reporter assays that showed association of the mutations with increased promoter activity, various studies have reproducibly shown higher TERT expression in tumors with than without the promoter mutations. 58, 59, 65, 115 The mutations not only result in an increased TERT expression but also in increased telomerase activity as shown in various studies. 115 Specifically in experiments on urothelial cell carcinoma cell lines, the promoter mutations were shown to be associated with 18-fold increase in TERT expression and a two-fold increased telomerase activity. 115 Introduction of different promoter mutations in pluripotent human embryonic stem and neural precursor cells showed continued expression of TERT following differentiation. 89 Usually differentiated cells do not exhibit any telomerase activity, those cells with TERT promoter mutations, in contrast, showed the enzymatic activity comparable to immortal tumor cell lines. 89 At onset of the discovery, it was speculated that the TERT promoter mutations lead to the de novo creation of the binding sites for the ETS/TCF transcription factors. Experimental confirmation came through specific binding of an multimeric ETS family member, GA-binding protein, alpha subunit (GABPA) as a heteromeric complex with GABP1 in cooperation with native sites in proximity to the de novo sites generated by the TERT promoter mutations. 116 A study based on a proteomewide survey showed a complex competitive recruitment of GABPA enabled by spatial arrangement of native and newly created ETS sites through displacement of initially recruited ELF1 transcription factors at the latter sites. 117 Another study showed requirement of non-canonical NF-kB signaling involving cooperativity between p52/RelB and ETS1 for binding at the site created specifically by 2146 C > T, one of the main TERT promoter mutations. 118 Mechanistic studies have shown the TERT promoter mutations to cause massive epigenetic change on the mutant allele from H3K27me3 to H3K4me2/3, a mark of active chromatin, along with recruitment of pol II following the binding of GABPA/B1 complex leading to monoallelic expression. 119 Another study showed that recruitment of GABPA transcription factor at the sites created by mutations mediates a long range chromatin interaction with sequence elements 300 kb upstream and enrichment of active histone marks and subsequent POL2 recruitment. 120 Among other noncoding somatic mutations, the acquired heterozygous insertions in T-ALL create binding motifs for MYB transcription factor that result in formation of a superenhancer upstream of the TAL1 oncogene. Binding of MYB at the de novo sites leads to recruitment of its H3K27 acetylase-binding partner CBP along with core components of a major leukemogenic complex. 77 Similarly, the C > T somatic mutation in noncoding sequences 4 kb upstream of transcriptional start site of the LMO1 in T-ALL, generates a new binding site for the MYB transcription factor leading to the formation of an aberrant transcriptional complex that drives up the expression the LMO1 oncogene. 78 The mutations detected in 3' UTR of NOTCH1 result in novel splicing events in chronic lymphocytic leukemia. 81 The small intergenic region of chromosome 9p13 with recurrent mutations in chronic lymphocytic leukemia was shown to be enriched for lymphocyte-specific transcription factor binding sites and histone marks related to enhancer elements in a lymphoblastoid B-cell line. And the mutations in the region through three-dimensional interaction lead to reduced expression of the B-cell specific transcription factor PAX5. 81 The exact functionality of the noncoding mutations within a bidirectional promoter of DPH3 and OXNAD1 has remained unclear. 71 Similarly, the understanding of role of other noncoding mutations in different cancers, that have begun to emerge with an increased regularity through whole genome sequencing, remains in the initial stages. 
Conclusions
From identification of disease associated germline variants within noncoding regions of the genome to identification of cis-acting elements that control gene expression, the studies have uniquely emphasized the role of regulatory elements. Many of the disease associated germline noncoding variants act through transcriptional alterations of the target genes. Data emerging from whole genome sequencing for various cancers have also shown regular detection of recurrent somatic mutations within the noncoding parts of the human genome. The enrichment of alterations, in particular the disease associated germline variants identified through genome wide association studies, within the regulatory elements and impact on transcription of critical genes evidently implicates noncoding regions of the genome as bonafide targets of selection in pathological cellular dysregulation. Discovery of the promoter mutations, which upregulate TERT expression in cancers through massive epigenetic alterations on the mutant allele, has brought to the forth a number of new potential targets of therapeutic intervention. A number of studies have shown the prognostic relevance of TERT promoter mutations through association with different clinical parameters and patient outcomes. Disproportionately vast size of the noncoding compared to coding genome with plethora of elements involved in cis and trans-regulation of genetic transcription, through complex epigenetic mechanisms, would imply many more alterations affecting those processes remain to be identified.
